Tempo Bioscience

Executive Summary

Tempo Bioscience, founded in 2020 and headquartered in San Diego, is a preclinical-stage biotechnology company specializing in in vitro models of biological barriers. The company leverages Transwell assays and TEER (transepithelial/transendothelial electrical resistance) measurements to evaluate barrier integrity and drug transport, with applications spanning oncology, immunology, and cell therapy. Their platform enables researchers to model complex barrier functions, offering insights into drug permeability, tight-junction dynamics, and disease pathology. By providing standardized, reproducible assays, Tempo aims to accelerate preclinical drug development and reduce reliance on animal models. Despite being early-stage, Tempo's focus on high-demand tools for drug transport and barrier biology positions it as a potential enabler for pharmaceutical and biotechnology partners. The company's technology addresses critical bottlenecks in screening candidate therapeutics for central nervous system disorders, inflammatory diseases, and cancer. Upcoming milestones include expected Series A financing to scale operations, publication of key validation data, and potential strategic partnerships with larger drug developers. However, the company faces typical early-stage risks including limited commercial traction and competition from established assay providers.

Upcoming Catalysts (preview)

• Q2 2026Series A Financing Round70% success
• Q3 2026Publication of Preclinical Data in Peer-Reviewed Journal80% success
• Q4 2026Strategic Partnership with Pharma for Drug Transport Assays60% success